Table S3.
Adverse events for GT1 patients
| Common adverse events | Patients receiving IFN-based therapy (n=17) N (%) | Theoretical patients receiving SOF/LDV (n=100)a N (%) |
|---|---|---|
| Fatigueb | 14 (82) | 28 (28) |
| Headache | 11 (65) | 25 (25) |
| Insomnia | 10 (59) | 8 (8) |
| Nausea | 7 (41) | 11 (11) |
| Diarrhea | 5 (29) | 11 (11) |
| Rash | 9 (53) | 7 (7) |
| Irritability | 8 (47) | 5 (5) |
| Cough | 9 (53) | 3 (3) |
| Pruritus | 8 (73) | 5(5) |
| Hematological adverse events | ||
| Hb | ||
| <100 (gL−1) | 9 (53) | 0 (0) |
| <85 (gL−1) | 3 (18) | 0(0) |
| Lymphocytes | ||
| <0.35 (×109 L−1) | 0 (0) | 0(0) |
| Neutrophil <0.75 (×109 L−1) | 7 (41) | 1 (1) |
| Platelet count <50 (×109 L−1) | 2 (12) | 1 (1) |
Notes:
a
Derived from ION-1 trial (Afdhal et al1).
b
To facilitate comparison, cases of “asthenia” were included under fatigue.
Abbreviations: GT1, genotype 1; Hb, hemoglobin; IFN, interferon; LDV, ledipasvir; SOF, sofosbuvir.